Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions

Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies that use the end points of acute coronary syndromes and death provide direct information on the effects of various therapies but require large samples and prolonged periods of study. Since the risk of coronary events is related to the progression of coronary lesions, 1 a highly relevant clinical end point is the attenuation of plaque formation. Studies using coronary angiography . . .